Ovid Therapeutics Inc.
OVID· Nasdaq
Released Aug 9, 2018, after the close
10-Q filed Aug 9, 2018, 40 days after period end · 0001564590-18-021111
| Metric | Q2 2018 | Q2 2017 | Q2 2016 |
|---|---|---|---|
| Net Income | -$12.94M | -$10.25M | -$5.39M |
| EPS Diluted | -$0.53 | -$0.57 | -$0.55 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ovid Therapeutics Inc. · CIK 1636651 · Engraved from SEC EDGAR
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
ended Jun 30, 2018 · filed Aug 9, 2018 · 40 d after period end
0.3% from the close of Aug 6, 2018 to the close of Aug 13, 2018, the first after the release.